STEP-HFpEF [14] demonstrated that semaglutide improved symptoms, exercise capacity, NT-proBNP, and body weight in obese patients, while SUMMIT [35] further extended these findings by showing that tirzepatide not only improved symptoms and biomarkers but also reduced HF hospitalizations and composite clinical outcomes. Here, NPPB is linked to hydrops fetalis.